SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: March 15, 1997, 1997
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer
Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS
The registrant incorporates by reference herein the press
release dated March 18, 1997, attached hereto as Exhibit 99.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(i) Exhibit 99 -- Press Release dated March 18, 1997.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
LIDAK PHARMACEUTICALS
Date: March 24, 1997 By:/s/David H. Katz
------------------------------
David H. Katz, M.D.
President and Chief Executive
Officer
<PAGE>
EXHIBIT 99
DATE: MARCH 18, 1997 LIDAK PHARMACEUTICALS CONTACT: Lisa Dawn Katz
NEWS RELEASE Director,
Communications &
Investor Relations
LIDAKPharmaceuticals
(619) 558-0364,
ext. 256
David H. Katz,M.D.
President/CEO
LIDAK Pharmaceuticals
(619) 450-1538
LIDAK PHARMACEUTICALS ADDS NEW VICE PRESIDENT AND REPORTS
DRUG DEVELOPMENT HIGHLIGHTS AT ANNUAL MEETING
LA JOLLA, CALIFORNIA -- March 18, 1997 -- In his report to
shareholders at the March 15, 1997 annual meeting of LIDAK Pharmaceuticals
(Nasdaq NNM: LDAKA), Dr. David H. Katz, LIDAK's Chief Executive Officer,
announced the promotion of James E. Berg to the new position of Vice
President of Clinical Affairs and Product Development. For the past five
years Mr. Berg has held the position of Director of Clinical Affairs and
Product Development at LIDAK. Prior to joining LIDAK Mr. Berg was employed
by QUIDEL Corporation, where from 1984 to 1992, he held positions as
Regional Manager, Autoimmune Products, National Accounts Manager, Director
of Materials, Materials Manager and Product Manager. "This is a well-
deserved promotion for one of LIDAK's most dedicated, hard-working and
effective team members," said Dr. Katz.
Dr. Katz also updated shareholders on the state of several of the
Company's ongoing product development programs. The most advanced program
involves the ongoing Phase 3 clinical trials with the topical formulation
of LIDAK's proprietary drug, n-docosanol (LIDAKOL_), as a treatment of oral
herpes. These studies are being conducted on over six hundred patients at
22 clinical sites around the United States. The trials are on schedule for
completion and data availability by the third quarter of the year, as
previously reported.
Commenting on progress in the Company's preclinical programs, Katz
reported that the rapid screening technology, announced late last year, for
identifying novel compounds that suppress production of allergy-causing IgE
antibodies has yielded four promising new drug candidates for potential
treatment of allergies and asthma. "These results are encouraging not only
because of the new potential drugs that have been discovered, but also for
the speed of the discovery process which supports our hopes for the value
of this rapid screening technology,"
Dr. Katz stated.
LIDAK Pharmaceuticals is developing therapeutic products against
virally caused diseases, inflammatory disorders and cancer.
# # #
The information contained in this press release should be reviewed in
conjunction with the Company's Annual Report on Form 10-K and other
publicly available information regarding the Company, copies of which are
available from the Company upon request. Such publicly available
information sets forth many risks and uncertainties related to the
Company's business, including risks and uncertainties related to drug
development and clinical trials.
